ArticleFrontiers in endocrinology2026
Association between triglyceride glucose index and odds of hip fracture in patients with or without type 2 diabetes: a cross-sectional study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The triglyceride-glucose (TyG) index, an indicator of insulin resistance, has demonstrated variable correlations with fracture risk. This study sought to examine the correlation between TyG and the odds of hip fractures in Chinese individuals, both with and without type 2 diabetes (T2D). Methods: This retrospective cross-sectional study was performed at Changzhou Second People's Hospital and involved 935 Chinese individuals, including 248 patients with hip fractures. TyG was calculated based on fasting glucose and triglyceride levels. Multivariate logistic regression models were used to investigate the association between TyG and the odds of hip fracture. Results: The odds of hip fractures was identical in both T2D and non-T2D groups (27.5% vs 26.3%, P = 0.734). After adjusting for all confounders, increasing TyG significantly reduced the odds of hip fracture in the group without T2D (odds ratio [OR] = 0.45; 95% confidence interval [CI]:0.25-0.83), but not in the T2D group (OR = 1.90; 95% CI:0.81-4.46). A significant multiplicative interaction was observed between T2D and TyG on the odds of hip fracture (p for interaction < 0.01). In addition, there is no association between TyG and bone mineral density (BMD) in either the T2D or without T2D participants (p > 0.05). Conclusion: Significant elevations in TyG were independently associated with a reduced odds of hip fractures in Chinese individuals without T2D, but not in those with T2D. These findings underscore the necessity of considering diabetes status when evaluating the TyG index as a metabolic determinant of hip fracture odds in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.